PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer

Cell Reports

Volumn 15, Issue 12, 2016, Pages 2692-2704

  Spangle, Jennifer M ^a,b   Dreijerink, Koen M ^a,b   Groner, Anna C ^a,b   Cheng, Hailing ^a,c   Ohlson, Carolynn E ^a   Reyes, Jaime ^a   Lin, Charles Y ^a   Bradner, James ^a   Zhao, Jean J ^a,b   Roberts, Thomas M ^a,b   Brown, Myles ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE H3K4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA BINDING PROTEIN 2; UNCLASSIFIED DRUG; KDM5A PROTEIN, HUMAN; LYSINE;

ADVANCED CANCER; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLYSIS; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BREAST TUMOR; CELL CYCLE; CELL FRACTIONATION; CHEMISTRY; ENZYME ACTIVATION; ENZYME SPECIFICITY; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHYLATION; PATHOLOGY; PROMOTER REGION; PROTEIN TRANSPORT; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL CYCLE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LYSINE; METHYLATION; MICE; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RETINOBLASTOMA-BINDING PROTEIN 2; SUBCELLULAR FRACTIONS; SUBSTRATE SPECIFICITY; TREATMENT OUTCOME;

EID: 84975144711     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.046     Document Type: Article

References (52)

1. Benard A., Goossens-Beumer I.J., van Hoesel A.Q., de Graaf W., Horati H., Putter H., Zeestraten E.C., van de Velde C.J., Kuppen P.J. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer 2014, 14:531.
2. Benevolenskaya E.V., Murray H.L., Branton P., Young R.A., Kaelin W.G. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol. Cell 2005, 18:623-635.
3. Borkin D., He S., Miao H., Kempinska K., Pollock J., Chase J., Purohit T., Malik B., Zhao T., Wang J., et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 2015, 27:589-602.
4. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
5. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
6. Cao F., Townsend E.C., Karatas H., Xu J., Li L., Lee S., Liu L., Chen Y., Ouillette P., Zhu J., et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 2014, 53:247-261.
7. Cao J., Liu Z., Cheung W.K., Zhao M., Chen S.Y., Chan S.W., Booth C.J., Nguyen D.X., Yan Q. Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep. 2014, 6:868-877.
8. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
9. Cha T.L., Zhou B.P., Xia W., Wu Y., Yang C.C., Chen C.T., Ping B., Otte A.P., Hung M.C. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
10. Christensen J., Agger K., Cloos P.A., Pasini D., Rose S., Sennels L., Rappsilber J., Hansen K.H., Salcini A.E., Helin K. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 2007, 128:1063-1076.
11. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
12. Feng J., Liu T., Qin B., Zhang Y., Liu X.S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 2012, 7:1728-1740.
13. Ge Z., Li W., Wang N., Liu C., Zhu Q., Björkholm M., Gruber A., Xu D. Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J. 2010, 24:579-586.
14. Gera J.F., Mellinghoff I.K., Shi Y., Rettig M.B., Tran C., Hsu J.H., Sawyers C.L., Lichtenstein A.K. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 2004, 279:2737-2746.
15. Hamamoto R., Saloura V., Nakamura Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat. Rev. Cancer 2015, 15:110-124.
16. Hou J., Wu J., Dombkowski A., Zhang K., Holowatyj A., Boerner J.L., Yang Z.Q. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am. J. Transl. Res. 2012, 4:247-256.
17. Jiping Z., Ming F., Lixiang W., Xiuming L., Yuqun S., Han Y., Zhifang L., Yundong S., Shili L., Chunyan C., Jihui J. MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. J. Cell. Biochem. 2013, 114:2666-2672.
18. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
19. Juric D., Castel P., Griffith M., Griffith O.L., Won H.H., Ellis H., Ebbesen S.H., Ainscough B.J., Ramu A., Iyer G., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 2015, 518:240-244.
20. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
21. Klose R.J., Yan Q., Tothova Z., Yamane K., Erdjument-Bromage H., Tempst P., Gilliland D.G., Zhang Y., Kaelin W.G. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 2007, 128:889-900.
22. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
23. Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009, 10:R25.
24. Lee T.I., Johnstone S.E., Young R.A. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 2006, 1:729-748.
25. Liefke R., Oswald F., Alvarado C., Ferres-Marco D., Mittler G., Rodriguez P., Dominguez M., Borggrefe T. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev. 2010, 24:590-601.
26. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D.J., Chen C., Fox E.A., et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17:1116-1120.
27. Liu Y., Liu F., Yu H., Zhao X., Sashida G., Deblasio A., Harr M., She Q.B., Chen Z., Lin H.K., et al. Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci. Signal. 2012, 5:ra77.
28. Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., Gan W., Papa A., Kim B.M., et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014, 508:541-545.
29. Lopez-Bigas N., Kisiel T.A., Dewaal D.C., Holmes K.B., Volkert T.L., Gupta S., Love J., Murray H.L., Young R.A., Benevolenskaya E.V. Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol. Cell 2008, 31:520-530.
30. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
31. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
32. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
33. Meier R., Alessi D.R., Cron P., Andjelković M., Hemmings B.A. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J. Biol. Chem. 1997, 272:30491-30497.
34. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstråle M., Laurila E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
35. Mungamuri S.K., Murk W., Grumolato L., Bernstein E., Aaronson S.A. Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers. Cell Rep. 2013, 5:302-313.
36. Obenauer J.C., Cantley L.C., Yaffe M.B. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003, 31:3635-3641.
37. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
38. Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43:e47.
39. Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013, 10:143-153.
40. Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc. Natl. Acad. Sci. USA 2013, 110:3895-3900.
41. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
42. Secombe J., Li L., Carlos L., Eisenman R.N. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev. 2007, 21:537-551.
43. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
44. Songyang Z., Blechner S., Hoagland N., Hoekstra M.F., Piwnica-Worms H., Cantley L.C. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 1994, 4:973-982.
45. Thorpe L.M., Yuzugullu H., Zhao J.J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 2015, 15:7-24.
46. Trapnell C., Pachter L., Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25:1105-1111.
47. Trapnell C., Williams B.A., Pertea G., Mortazavi A., Kwan G., van Baren M.J., Salzberg S.L., Wold B.J., Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 2010, 28:511-515.
48. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., Albarracin C., Yu D., Abbruzzese J.L., Mills G.B., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 2008, 47:701-706.
49. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., Wu X., Stack E.C., Loda M., Liu T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012, 338:1465-1469.
50. Yamamoto S., Wu Z., Russnes H.G., Takagi S., Peluffo G., Vaske C., Zhao X., Moen Vollan H.K., Maruyama R., Ekram M.B., et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 2014, 25:762-777.
51. Zeng J., Ge Z., Wang L., Li Q., Wang N., Björkholm M., Jia J., Xu D. The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010, 138:981-992.
52. Zhu J., Sammons M.A., Donahue G., Dou Z., Vedadi M., Getlik M., Barsyte-Lovejoy D., Al-awar R., Katona B.W., Shilatifard A., et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015, 525:206-211.